Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment

Angela M Abbatecola, Fabrizia Lattanzio, Anna M Molinari, Michele Cioffi, Luigi Mansi, Pierfrancesco Rambaldi, Luigi DiCioccio, Federico Cacciapuoti, Raffaele Canonico, Giuseppe Paolisso, Angela M Abbatecola, Fabrizia Lattanzio, Anna M Molinari, Michele Cioffi, Luigi Mansi, Pierfrancesco Rambaldi, Luigi DiCioccio, Federico Cacciapuoti, Raffaele Canonico, Giuseppe Paolisso

Abstract

Objective: Studies have suggested that insulin resistance plays a role in cognitive impairment in individuals with type 2 diabetes. We aimed to determine whether an improvement in insulin resistance could explain cognitive performance variations over 36 weeks in older individuals with mild cognitive impairment (MCI) and type 2 diabetes.

Research design and methods: A total of 97 older individuals (mean +/- SD age 76 +/- 6 years) who had recently (<2 months) started an antidiabetes treatment of metformin (500 mg twice a day) (n = 30) or metformin (500 mg/day)+rosiglitazone (4 mg/day) (n = 32) or diet (n = 35) volunteered. The neuropsychological test battery consisted of the Mini-Mental State Examination (MMSE), Rey Verbal Auditory Learning Test (RAVLT) total recall, and Trail Making Tests (TMT-A and TMT-B) performed at baseline and every 12 weeks for 36 weeks along with clinical testing.

Results: At baseline, no significant differences were found between groups in clinical or neuropsychological parameters. Mean +/- SD values in the entire population were as follows: A1C 7.5 +/- 0.5%, fasting plasma glucose (FPG) 8.6 +/- 1.3 mmol/l, fasting plasma insulin (FPI) 148 +/- 74 pmol/l, MMSE 24.9 +/- 2.4, TMT-A 61.6 +/- 42.0, TMT-B 162.8 +/- 78.7, the difference between TMT-B and TMT-A [DIFFBA] 101.2 +/- 58.1, and RAVLT 24.3 +/- 2.1. At follow-up, ANOVA models tested changes in metabolic control parameters (FPI, FPG, and A1C). Such parameters improved in the metformin and metformin/rosiglitazone groups (P(trend) < 0.05 in both groups). ANCOVA repeated models showed that results for the metformin/rosiglitazone group remained stable for all neuropsychological tests, and results for the diet group remained stable for the MMSE and TMT-A and declined for the TMT-B (P(trend) = 0.024), executive efficiency (DIFFBA) (P(trend) = 0.026), and RAVLT memory test (P(trend) = 0.011). Results for the metformin group remained stable for the MMSE and TMTs but declined for the RAVLT (P(trend) = 0.011). With use of linear mixed-effects models, the interaction term, FPI x time, correlated with cognitive stability on the RAVLT in the metformin/rosiglitazone group (beta = -1.899; P = 0.009).

Conclusions: Rosiglitazone may protect against cognitive decline in older individuals with type 2 diabetes and MCI.

Figures

Figure 1
Figure 1
Patient recruitment flow diagram. *Oral antidiabetes drug initiated within the last 2 months. §According to data of Petersen (2004)(15). aMCI, amnestic MCI.
Figure 2
Figure 2
Changes in A1C, cardiovascular PPG, and FPG over time according to antidiabetic treatment. ▲, D group; ○, MF/Rosi group; ■, MF. *Ptrend < 0.05 within the group over time. PPG = postprandial glucose, FPG = fasting plasma glucose.

References

    1. Messier C, Gagnon M: Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Diabetologia 2009;52:2471–2474
    1. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, Vella A, Rocca WA, Petersen RC: Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008;65:1066–1073
    1. Biessels GJ, Kappelle LJ: Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 2005;33:1041–1044
    1. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW: Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006;29:345–351
    1. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001;108:1341–1348
    1. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, Acampora R, Passariello N, Cacciapuoti F, Paolisso G: Post prandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006;67:235–240
    1. Watson GS, Craft S: Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004;490:97–113
    1. Folli F, Ghidella S, Bonfanti L, Kahn CR, Merighi A: The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Mol Neurobiol 1996;13:155–183
    1. Folli F, Bonfanti L, Renard E, Kahn CR, Merighi A: Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci 1994;14:6412–6422
    1. Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, Ferrucci L: Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 2004;52:1713–1718
    1. Rönnemaa E, Zethelius B, Sundelöf J, Sundström J, Degerman-Gunnarsson M, Berne C, Lannfelt L, Kilander L: Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008;71:1065–1071
    1. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950–958
    1. Mancia G, Grassi G: The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. Ther Adv Cardiovasc Dis. 2008;2:5–12
    1. Brown PJ, Woods CM, Storandt M: Model stability of the 15-item Geriatric Depression Scale across cognitive impairment and severe depression. Psychol Aging 2007;22:372–379
    1. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–194
    1. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE: Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Public Health Nutr 2003;6:407–413
    1. Lezak M, Howieson D, Loring D: Neuropsychological Assessment. 4th ed. Oxford, U.K., Oxford University Press, 2004; pp 381–384, 438,–445, 741–744
    1. Ratcliff G, Dodge H, Birzescu M, Ganguli M: Tracking cognitive functioning over time: ten-year longitudinal data from a community-based study. Appl Neuropsychol 2003;10:76–88
    1. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ: Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Diabetes Care 2009;32:221–226
    1. Messier C, Gagnon M: Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 1996;75:1–11
    1. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S: Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162–4167
    1. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T: Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57:177–179
    1. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J: PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865–873
    1. Open-label extension study of rosiglitazone XR as adjunctive therapy in subjects with mild-to-moderate Alzheimers [article online], 2010. Available from . Accessed 01 October 2009
    1. Study of rosiglitazone XR in subjects with mild-to-moderate Alzheimers [article online], 2010. Available from . Accessed 01 October 2009

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다